RC48 Clinical Trials

4 actively recruiting trials

Also known as: Disitamab Vedotin

Pipeline

Phase 2: 3Phase 1/2: 1

Top Sponsors

Tianjin Medical University Second Hospital1
The First Affiliated Hospital with Nanjing Medical University1
RenJi Hospital1
Fudan University1

Indications

Cancer4
CDK12 Gene Mutation1
GC/GEJC1
Mammary or Extramammary Paget's Disease1
HER21

Other4 trials

A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.

Phase 2

Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial

Phase 2

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Phase 2

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.